FindTrial
Sign In

A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00189800
Enrollment
Unknown
Registered
2005-09-19
Start date
Unknown
Completion date
Unknown
Last updated
2011-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive Bladder

Keywords

Solifenacin, tolterodine, randomized controlled trial, double-blind method

Brief summary

The purpose of this study is to ascertain the clinical results of solifenacin succinate of PIII study conducted in the original country using Korean patients with an overactive bladder.

Interventions

DRUGSolifenacin succinate

Sponsors

Astellas Pharma Korea, Inc.
CollaboratorINDUSTRY
Astellas Pharma Inc
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Symptoms of overactive bladder * Must be able to complete the micturition diary

Exclusion criteria

* Pregnant or lactating * Clinically significant outflow obstruction * Significant post void residual urine * Significant stress incontinence * Urinary tract infection * Chronic inflammation * Bladder stones * Previous pelvic radiation therapy * Previous or current malignant disease of the pelvic organs * Uncontrolled narrow angle glaucoma * Urinary or gastric retention * Electrostimulation therapy * Bladder training * Diabetic neuropathy

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026